NICE still wants more info on RoActemra for RA patients
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has again asked Roche for more information on RoActemra (tocilizumab) before it decides whether to recommend it for treating some rheumatoid arthritis (RA) patients on the NHS.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.